US FDA Chief Scientist Wants To Make Advisory Committee Participation Easier

 
• By Sarah Karlin-Smith

Namandjé Bumpus says hybrid panels are the future and stakeholders should not oversimplify coming committee reform into just a voting or non-voting meeting binary.

FDA White Oak headquarters
FDA’s chief scientist doesn’t envision advisory panels ever fully returning to White Oak-only. • Source: Shutterstock/JHVEPhoto

More from US FDA Performance Tracker

More from Regulatory Trackers